Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study

NCT06573593 · clinicaltrials.gov ↗

RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Alopecia Areata
Janus Kinase Inhibitors

Interventions

DRUG: Tofacitinib
DRUG: Baricitinib
DRUG: Ruxolitinib
DRUG: Upadacitinib
DRUG: Abrocitinib
DRUG: Ritlecitinib

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University